微創醫療(00853.HK)斥600萬坡元戰投NDR及擬設合營使NDR穿刺導航機器人系統商業化
格隆匯5月6日丨微創醫療(00853.HK)發佈公告，於2020年5月6日，公司與NDR Medical Technology Private Limited（NDR）訂立正式協議，以帶領對NDR進行800萬新加坡元的戰略性投資。公司承諾投資600萬新加坡元，以換取NDR約20.9％的經擴大股權。
就該投資而言，公司附屬公司微創優通醫療科技（嘉興）有限公司亦已與NDR及上海佑隆企業管理諮詢中心（有限合夥）訂立協議，成立一家中國合營公司，以申請NMPA監管批准並使NDR的穿刺導航機器人系統商業化；建立上述系統的製造生產，以在大中華地區進行分銷；及開展與新一代產品相關的研發活動。
合營企業的註冊股本為人民幣2500萬元。優通、NDR及上海佑隆將分別投資人民幣1025萬元、人民幣975萬元及人民幣500萬元以換取合營企業41%、39%及20%的股權。
NDR為於新加坡註冊成立並從事研發用於經皮腎結石移除及╱或經皮肺活檢及消融手術的穿刺導航機器人系統的醫療器械公司。截至本公告日期，其由創辦人Ng Ka Wei先生及Goh Jin Quan先生持有約74.6%。
公司稱，NDR開發了兩個機器人手術輔助系統，這些系統將機器人硬件與專有自動穿刺定位(ANT)軟件相結合。這種由機器人控制的導引裝置可對針進行定位，以使其以最安全的路線進入人體併到達目標器官位置，從而最大程度地減少導致沿途重要器官及血管穿孔的風險。NDR專有的人工智能驅動算法，可分析手術過程中送入ANT系統的實時熒光透視和計算機斷層掃描圖像，用於定位穿刺針，以確保通過人體的安全有效軌跡。其ANT-X機器人系統將被指定用於經皮腎鏡取石手術，這是一種微創手術，可通過皮膚上的小刺傷從腎臟移除結石。其ANT-C機器人系統將用於經皮肺活檢及消融手術。
通過降低上述手術的複雜性並提高其安全性，集團認為，使用機器人輔助系統（如ANT-X及ANT-C）可以幫助治療大部分可能缺乏熟練於此手術的醫生的中國地區的未經治療的腎結石及肺部疾病患者。該投資及合營企業將使集團成為NDR股東，藉此推動與NDR的合作，於大中華市場商業化其創新的專有穿刺導航機器人系統產品，亦為集團提供額外平台發展其產品及服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
